Skip to content
CompoundSci
All peptides
Research vial labelled Ipamorelin, a Growth hormone secretagogue peptide studied in preclinical and clinical literature

Ipamorelin

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

The most receptor-selective ghrelin mimetic studied, with little cortisol or prolactin movement at research amounts.

General profile

Class
Growth hormone secretagogue
Evidence
Mixed or moderate evidence
Studied dose range
0.1–0.3 mg
Frequency in protocols
1–2× daily, fasted
Route
Subcutaneous
Half life
~2 hours
Reconstitution
2 mL bacteriostatic water per 5 mg vial
Storage
Refrigerated, ~30 days

Timing and cycling in the literature

Usually dosed in the bedtime window, fasted

One to two times daily, fasted

Ghrelin receptor signalling is suppressed by circulating insulin, so protocols place it in a fasted window, usually before sleep.

Reported cycle: 12 weeks on, 4 weeks off

Selective secretagogue protocols follow the same multi-month arc as the GHRH analogs they are paired with.

Watch for: Hunger spikes, water retention, and fasting glucose.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    Ipamorelin + CJC-1295 + Ipamorelin

    Duplicate ingredient

    The blend already contains ipamorelin. Adding standalone ipamorelin on top is a straightforward double dose of the same secretagogue.

  • Pick oneRedundant, pick one

    Ipamorelin + CJC-1295 + Ipamorelin

    Same target hit twice

    The blend already contains ipamorelin. Adding more is receptor competition, not a cleaner pulse.

  • Pick oneRedundant, pick one

    Ipamorelin + Tesamorelin + Ipamorelin

    Same target hit twice

    The blend already contains ipamorelin.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Ipamorelin fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature